- Jasper Therapeutics reports 89% complete response rate in briquilimab trials for Chronic Spontaneous Urticaria (CSU).
- Operational challenges arise due to drug product lot issues, delaying Phase 2b study until mid-2026.
- Company halts ETESIAN asthma study and SCID development, implementing cost-cutting measures.
Jasper Therapeutics (JSPR, Financial) has revealed promising yet mixed results from its BEACON study involving briquilimab for the treatment of Chronic Spontaneous Urticaria (CSU). Notably, in the single-dose cohorts of 240mg and 360mg, 89% of participants achieved a complete response. The open-label extension study further exhibited a 73% complete response rate at 12 weeks using a 180mg Q8W dosing regimen.
However, complications have emerged due to issues with a specific drug product lot affecting the 240mg Q8W and 240mg followed by 180mg Q8W cohorts. These issues led to lower than expected tryptase reductions and no significant improvement in UAS7 scores, necessitating an investigation into the affected lot.
To address the lot-specific problem, Jasper is transitioning affected patients to a new drug product and plans to enroll an additional 10-12 patients across the impacted cohorts. This step aims to provide robust data for the Phase 2b CSU study, which has been postponed to mid-2026.
In response to these challenges, Jasper Therapeutics is halting the ETESIAN asthma study and SCID development while also implementing cost-cutting measures to extend its financial runway. Despite these setbacks, briquilimab continues to show a favorable safety profile, with no grade 3 or higher treatment-related adverse events reported during trials.
